Global Endocrine Disrupting Properties Assessment Supply, Demand and Key Producers, 2026-2032
The global Endocrine Disrupting Properties Assessment market size is expected to reach $ 329 million by 2032, rising at a market growth of 6.4% CAGR during the forecast period (2026-2032).
Endocrine Disrupting Properties Assessment refers to the scientific and regulatory evaluation of whether a chemical substance, mixture, ingredient, material or active substance has properties that may interfere with the endocrine system and lead to adverse effects in humans or the environment. The assessment typically integrates existing toxicological data, endocrine activity screening, mechanistic evidence, apical adverse-effect studies, exposure and relevance considerations, and a weight-of-evidence judgement based on recognized regulatory frameworks and test guidelines. In market terms, it covers laboratory testing, data gap analysis, study design, dossier review, expert interpretation and compliance support for chemicals, pesticides, biocides, cosmetics ingredients, industrial materials and other regulated substances. OECD guidance focuses on standardized test guidelines for evaluating chemicals for endocrine disruption, including estrogen, androgen, thyroid and steroidogenesis-related modalities, while EU regulatory frameworks have established scientific criteria for identifying endocrine disruptors in biocidal and plant protection product areas.
The Endocrine Disrupting Properties Assessment market is becoming an increasingly important segment of chemical safety, regulatory toxicology and compliance testing services. Demand is mainly driven by stricter regulatory attention to chemicals that may interfere with hormonal systems, especially under European chemical, biocidal product and plant protection product frameworks. The market is not limited to a single laboratory test, but combines in vitro screening, in vivo toxicology data, mechanistic interpretation, weight-of-evidence evaluation, regulatory dossier preparation and expert review. Service providers with strong experience in OECD test guidelines, ECHA and EFSA guidance, REACH, CLP, biocides, pesticides and cosmetics-related compliance are likely to gain advantages, because customers need not only test results, but also defensible scientific conclusions that can support product registration, substance approval, risk assessment and market access. OECD describes its work as supporting countries’ needs for testing and assessment of chemicals for endocrine disrupters, while ECHA maintains an endocrine disruptor assessment process and list for substances under assessment.
This report studies the global Endocrine Disrupting Properties Assessment demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Endocrine Disrupting Properties Assessment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Endocrine Disrupting Properties Assessment that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Endocrine Disrupting Properties Assessment total market, 2021-2032, (USD Million)
Global Endocrine Disrupting Properties Assessment total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Endocrine Disrupting Properties Assessment total market, key domestic companies, and share, (USD Million)
Global Endocrine Disrupting Properties Assessment revenue by player, revenue and market share 2021-2026, (USD Million)
Global Endocrine Disrupting Properties Assessment total market by Type, CAGR, 2021-2032, (USD Million)
Global Endocrine Disrupting Properties Assessment total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Endocrine Disrupting Properties Assessment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Labcorp, Eurofins Scientific, Intertek, Charles River Laboratories, PerkinElmer, Smithers, Fera Science, Staphyt, TransGenic, ToxStrategies, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Endocrine Disrupting Properties Assessment market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Endocrine Disrupting Properties Assessment Market, By Region:
1. How big is the global Endocrine Disrupting Properties Assessment market?
2. What is the demand of the global Endocrine Disrupting Properties Assessment market?
3. What is the year over year growth of the global Endocrine Disrupting Properties Assessment market?
4. What is the total value of the global Endocrine Disrupting Properties Assessment market?
5. Who are the Major Players in the global Endocrine Disrupting Properties Assessment market?
6. What are the growth factors driving the market demand?
Endocrine Disrupting Properties Assessment refers to the scientific and regulatory evaluation of whether a chemical substance, mixture, ingredient, material or active substance has properties that may interfere with the endocrine system and lead to adverse effects in humans or the environment. The assessment typically integrates existing toxicological data, endocrine activity screening, mechanistic evidence, apical adverse-effect studies, exposure and relevance considerations, and a weight-of-evidence judgement based on recognized regulatory frameworks and test guidelines. In market terms, it covers laboratory testing, data gap analysis, study design, dossier review, expert interpretation and compliance support for chemicals, pesticides, biocides, cosmetics ingredients, industrial materials and other regulated substances. OECD guidance focuses on standardized test guidelines for evaluating chemicals for endocrine disruption, including estrogen, androgen, thyroid and steroidogenesis-related modalities, while EU regulatory frameworks have established scientific criteria for identifying endocrine disruptors in biocidal and plant protection product areas.
The Endocrine Disrupting Properties Assessment market is becoming an increasingly important segment of chemical safety, regulatory toxicology and compliance testing services. Demand is mainly driven by stricter regulatory attention to chemicals that may interfere with hormonal systems, especially under European chemical, biocidal product and plant protection product frameworks. The market is not limited to a single laboratory test, but combines in vitro screening, in vivo toxicology data, mechanistic interpretation, weight-of-evidence evaluation, regulatory dossier preparation and expert review. Service providers with strong experience in OECD test guidelines, ECHA and EFSA guidance, REACH, CLP, biocides, pesticides and cosmetics-related compliance are likely to gain advantages, because customers need not only test results, but also defensible scientific conclusions that can support product registration, substance approval, risk assessment and market access. OECD describes its work as supporting countries’ needs for testing and assessment of chemicals for endocrine disrupters, while ECHA maintains an endocrine disruptor assessment process and list for substances under assessment.
This report studies the global Endocrine Disrupting Properties Assessment demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Endocrine Disrupting Properties Assessment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Endocrine Disrupting Properties Assessment that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Endocrine Disrupting Properties Assessment total market, 2021-2032, (USD Million)
Global Endocrine Disrupting Properties Assessment total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Endocrine Disrupting Properties Assessment total market, key domestic companies, and share, (USD Million)
Global Endocrine Disrupting Properties Assessment revenue by player, revenue and market share 2021-2026, (USD Million)
Global Endocrine Disrupting Properties Assessment total market by Type, CAGR, 2021-2032, (USD Million)
Global Endocrine Disrupting Properties Assessment total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Endocrine Disrupting Properties Assessment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Labcorp, Eurofins Scientific, Intertek, Charles River Laboratories, PerkinElmer, Smithers, Fera Science, Staphyt, TransGenic, ToxStrategies, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Endocrine Disrupting Properties Assessment market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Endocrine Disrupting Properties Assessment Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- In Vitro (Cell-based) Testing
- In Vivo (Animal) Testing
- In Silico (Computational) Modeling
- Others
- Estrogen Pathway Assessment
- Androgen Pathway Assessment
- Thyroid Pathway Assessment
- Steroid Synthesis Pathway Assessment
- Others
- Environmental Monitoring
- Food Safety
- Cosmetics and Personal Care Products
- Public Health and Disease Prevention
- Others
- Labcorp
- Eurofins Scientific
- Intertek
- Charles River Laboratories
- PerkinElmer
- Smithers
- Fera Science
- Staphyt
- TransGenic
- ToxStrategies
- LAUS
- Creative Bioarray
- Creative Proteomics
- Compliance Services International
- Xenometrix
- Shenyang SYRICI Testing
1. How big is the global Endocrine Disrupting Properties Assessment market?
2. What is the demand of the global Endocrine Disrupting Properties Assessment market?
3. What is the year over year growth of the global Endocrine Disrupting Properties Assessment market?
4. What is the total value of the global Endocrine Disrupting Properties Assessment market?
5. Who are the Major Players in the global Endocrine Disrupting Properties Assessment market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Endocrine Disrupting Properties Assessment Introduction
1.2 World Endocrine Disrupting Properties Assessment Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Endocrine Disrupting Properties Assessment Total Market by Region (by Headquarter Location)
1.3.1 World Endocrine Disrupting Properties Assessment Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.3 China Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.4 Europe Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.5 Japan Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.6 South Korea Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.7 ASEAN Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.8 India Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Endocrine Disrupting Properties Assessment Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.2 World Endocrine Disrupting Properties Assessment Consumption Value by Region
2.2.1 World Endocrine Disrupting Properties Assessment Consumption Value by Region (2021-2026)
2.2.2 World Endocrine Disrupting Properties Assessment Consumption Value Forecast by Region (2027-2032)
2.3 United States Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.4 China Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.5 Europe Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.6 Japan Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.7 South Korea Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.8 ASEAN Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.9 India Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
3 WORLD ENDOCRINE DISRUPTING PROPERTIES ASSESSMENT COMPANIES COMPETITIVE ANALYSIS
3.1 World Endocrine Disrupting Properties Assessment Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Endocrine Disrupting Properties Assessment Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Endocrine Disrupting Properties Assessment in 2025
3.2.3 Global Concentration Ratios (CR8) for Endocrine Disrupting Properties Assessment in 2025
3.3 Endocrine Disrupting Properties Assessment Company Evaluation Quadrant
3.4 Endocrine Disrupting Properties Assessment Market: Overall Company Footprint Analysis
3.4.1 Endocrine Disrupting Properties Assessment Market: Region Footprint
3.4.2 Endocrine Disrupting Properties Assessment Market: Company Product Type Footprint
3.4.3 Endocrine Disrupting Properties Assessment Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Endocrine Disrupting Properties Assessment Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Endocrine Disrupting Properties Assessment Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Endocrine Disrupting Properties Assessment Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Endocrine Disrupting Properties Assessment Consumption Value Comparison
4.2.1 United States VS China: Endocrine Disrupting Properties Assessment Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Endocrine Disrupting Properties Assessment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Endocrine Disrupting Properties Assessment Companies and Market Share, 2021-2026
4.3.1 United States Based Endocrine Disrupting Properties Assessment Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Endocrine Disrupting Properties Assessment Revenue, (2021-2026)
4.4 China Based Companies Endocrine Disrupting Properties Assessment Revenue and Market Share, 2021-2026
4.4.1 China Based Endocrine Disrupting Properties Assessment Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Endocrine Disrupting Properties Assessment Revenue, (2021-2026)
4.5 Rest of World Based Endocrine Disrupting Properties Assessment Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Endocrine Disrupting Properties Assessment Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Endocrine Disrupting Properties Assessment Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Endocrine Disrupting Properties Assessment Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 In Vitro (Cell-based) Testing
5.2.2 In Vivo (Animal) Testing
5.2.3 In Silico (Computational) Modeling
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Endocrine Disrupting Properties Assessment Market Size by Type (2021-2026)
5.3.2 World Endocrine Disrupting Properties Assessment Market Size by Type (2027-2032)
5.3.3 World Endocrine Disrupting Properties Assessment Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY ENDOCRINE PATHWAY
6.1 World Endocrine Disrupting Properties Assessment Market Size Overview by Endocrine Pathway: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Endocrine Pathway
6.2.1 Estrogen Pathway Assessment
6.2.2 Androgen Pathway Assessment
6.2.3 Thyroid Pathway Assessment
6.2.4 Steroid Synthesis Pathway Assessment
6.2.5 Others
6.3 Market Segment by Endocrine Pathway
6.3.1 World Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway (2021-2026)
6.3.2 World Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway (2027-2032)
6.3.3 World Endocrine Disrupting Properties Assessment Market Size Market Share by Endocrine Pathway (2027-2032)
7 MARKET ANALYSIS BY APPLICATION
7.1 World Endocrine Disrupting Properties Assessment Market Size Overview by Application: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Application
7.2.1 Environmental Monitoring
7.2.2 Food Safety
7.2.3 Cosmetics and Personal Care Products
7.2.4 Public Health and Disease Prevention
7.2.5 Others
7.3 Market Segment by Application
7.3.1 World Endocrine Disrupting Properties Assessment Market Size by Application (2021-2026)
7.3.2 World Endocrine Disrupting Properties Assessment Market Size by Application (2027-2032)
7.3.3 World Endocrine Disrupting Properties Assessment Market Size Market Share by Application (2021-2032)
8 COMPANY PROFILES
8.1 Labcorp
8.1.1 Labcorp Details
8.1.2 Labcorp Major Business
8.1.3 Labcorp Endocrine Disrupting Properties Assessment Product and Services
8.1.4 Labcorp Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.1.5 Labcorp Recent Developments/Updates
8.1.6 Labcorp Competitive Strengths & Weaknesses
8.2 Eurofins Scientific
8.2.1 Eurofins Scientific Details
8.2.2 Eurofins Scientific Major Business
8.2.3 Eurofins Scientific Endocrine Disrupting Properties Assessment Product and Services
8.2.4 Eurofins Scientific Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.2.5 Eurofins Scientific Recent Developments/Updates
8.2.6 Eurofins Scientific Competitive Strengths & Weaknesses
8.3 Intertek
8.3.1 Intertek Details
8.3.2 Intertek Major Business
8.3.3 Intertek Endocrine Disrupting Properties Assessment Product and Services
8.3.4 Intertek Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.3.5 Intertek Recent Developments/Updates
8.3.6 Intertek Competitive Strengths & Weaknesses
8.4 Charles River Laboratories
8.4.1 Charles River Laboratories Details
8.4.2 Charles River Laboratories Major Business
8.4.3 Charles River Laboratories Endocrine Disrupting Properties Assessment Product and Services
8.4.4 Charles River Laboratories Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.4.5 Charles River Laboratories Recent Developments/Updates
8.4.6 Charles River Laboratories Competitive Strengths & Weaknesses
8.5 PerkinElmer
8.5.1 PerkinElmer Details
8.5.2 PerkinElmer Major Business
8.5.3 PerkinElmer Endocrine Disrupting Properties Assessment Product and Services
8.5.4 PerkinElmer Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.5.5 PerkinElmer Recent Developments/Updates
8.5.6 PerkinElmer Competitive Strengths & Weaknesses
8.6 Smithers
8.6.1 Smithers Details
8.6.2 Smithers Major Business
8.6.3 Smithers Endocrine Disrupting Properties Assessment Product and Services
8.6.4 Smithers Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.6.5 Smithers Recent Developments/Updates
8.6.6 Smithers Competitive Strengths & Weaknesses
8.7 Fera Science
8.7.1 Fera Science Details
8.7.2 Fera Science Major Business
8.7.3 Fera Science Endocrine Disrupting Properties Assessment Product and Services
8.7.4 Fera Science Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.7.5 Fera Science Recent Developments/Updates
8.7.6 Fera Science Competitive Strengths & Weaknesses
8.8 Staphyt
8.8.1 Staphyt Details
8.8.2 Staphyt Major Business
8.8.3 Staphyt Endocrine Disrupting Properties Assessment Product and Services
8.8.4 Staphyt Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.8.5 Staphyt Recent Developments/Updates
8.8.6 Staphyt Competitive Strengths & Weaknesses
8.9 TransGenic
8.9.1 TransGenic Details
8.9.2 TransGenic Major Business
8.9.3 TransGenic Endocrine Disrupting Properties Assessment Product and Services
8.9.4 TransGenic Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.9.5 TransGenic Recent Developments/Updates
8.9.6 TransGenic Competitive Strengths & Weaknesses
8.10 ToxStrategies
8.10.1 ToxStrategies Details
8.10.2 ToxStrategies Major Business
8.10.3 ToxStrategies Endocrine Disrupting Properties Assessment Product and Services
8.10.4 ToxStrategies Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.10.5 ToxStrategies Recent Developments/Updates
8.10.6 ToxStrategies Competitive Strengths & Weaknesses
8.11 LAUS
8.11.1 LAUS Details
8.11.2 LAUS Major Business
8.11.3 LAUS Endocrine Disrupting Properties Assessment Product and Services
8.11.4 LAUS Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.11.5 LAUS Recent Developments/Updates
8.11.6 LAUS Competitive Strengths & Weaknesses
8.12 Creative Bioarray
8.12.1 Creative Bioarray Details
8.12.2 Creative Bioarray Major Business
8.12.3 Creative Bioarray Endocrine Disrupting Properties Assessment Product and Services
8.12.4 Creative Bioarray Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.12.5 Creative Bioarray Recent Developments/Updates
8.12.6 Creative Bioarray Competitive Strengths & Weaknesses
8.13 Creative Proteomics
8.13.1 Creative Proteomics Details
8.13.2 Creative Proteomics Major Business
8.13.3 Creative Proteomics Endocrine Disrupting Properties Assessment Product and Services
8.13.4 Creative Proteomics Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.13.5 Creative Proteomics Recent Developments/Updates
8.13.6 Creative Proteomics Competitive Strengths & Weaknesses
8.14 Compliance Services International
8.14.1 Compliance Services International Details
8.14.2 Compliance Services International Major Business
8.14.3 Compliance Services International Endocrine Disrupting Properties Assessment Product and Services
8.14.4 Compliance Services International Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.14.5 Compliance Services International Recent Developments/Updates
8.14.6 Compliance Services International Competitive Strengths & Weaknesses
8.15 Xenometrix
8.15.1 Xenometrix Details
8.15.2 Xenometrix Major Business
8.15.3 Xenometrix Endocrine Disrupting Properties Assessment Product and Services
8.15.4 Xenometrix Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.15.5 Xenometrix Recent Developments/Updates
8.15.6 Xenometrix Competitive Strengths & Weaknesses
8.16 Shenyang SYRICI Testing
8.16.1 Shenyang SYRICI Testing Details
8.16.2 Shenyang SYRICI Testing Major Business
8.16.3 Shenyang SYRICI Testing Endocrine Disrupting Properties Assessment Product and Services
8.16.4 Shenyang SYRICI Testing Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.16.5 Shenyang SYRICI Testing Recent Developments/Updates
8.16.6 Shenyang SYRICI Testing Competitive Strengths & Weaknesses
9 INDUSTRY CHAIN ANALYSIS
9.1 Endocrine Disrupting Properties Assessment Industry Chain
9.2 Endocrine Disrupting Properties Assessment Upstream Analysis
9.3 Endocrine Disrupting Properties Assessment Midstream Analysis
9.4 Endocrine Disrupting Properties Assessment Downstream Analysis
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
1.1 Endocrine Disrupting Properties Assessment Introduction
1.2 World Endocrine Disrupting Properties Assessment Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Endocrine Disrupting Properties Assessment Total Market by Region (by Headquarter Location)
1.3.1 World Endocrine Disrupting Properties Assessment Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.3 China Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.4 Europe Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.5 Japan Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.6 South Korea Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.7 ASEAN Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.3.8 India Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Endocrine Disrupting Properties Assessment Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.2 World Endocrine Disrupting Properties Assessment Consumption Value by Region
2.2.1 World Endocrine Disrupting Properties Assessment Consumption Value by Region (2021-2026)
2.2.2 World Endocrine Disrupting Properties Assessment Consumption Value Forecast by Region (2027-2032)
2.3 United States Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.4 China Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.5 Europe Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.6 Japan Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.7 South Korea Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.8 ASEAN Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
2.9 India Endocrine Disrupting Properties Assessment Consumption Value (2021-2032)
3 WORLD ENDOCRINE DISRUPTING PROPERTIES ASSESSMENT COMPANIES COMPETITIVE ANALYSIS
3.1 World Endocrine Disrupting Properties Assessment Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Endocrine Disrupting Properties Assessment Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Endocrine Disrupting Properties Assessment in 2025
3.2.3 Global Concentration Ratios (CR8) for Endocrine Disrupting Properties Assessment in 2025
3.3 Endocrine Disrupting Properties Assessment Company Evaluation Quadrant
3.4 Endocrine Disrupting Properties Assessment Market: Overall Company Footprint Analysis
3.4.1 Endocrine Disrupting Properties Assessment Market: Region Footprint
3.4.2 Endocrine Disrupting Properties Assessment Market: Company Product Type Footprint
3.4.3 Endocrine Disrupting Properties Assessment Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Endocrine Disrupting Properties Assessment Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Endocrine Disrupting Properties Assessment Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Endocrine Disrupting Properties Assessment Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Endocrine Disrupting Properties Assessment Consumption Value Comparison
4.2.1 United States VS China: Endocrine Disrupting Properties Assessment Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Endocrine Disrupting Properties Assessment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Endocrine Disrupting Properties Assessment Companies and Market Share, 2021-2026
4.3.1 United States Based Endocrine Disrupting Properties Assessment Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Endocrine Disrupting Properties Assessment Revenue, (2021-2026)
4.4 China Based Companies Endocrine Disrupting Properties Assessment Revenue and Market Share, 2021-2026
4.4.1 China Based Endocrine Disrupting Properties Assessment Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Endocrine Disrupting Properties Assessment Revenue, (2021-2026)
4.5 Rest of World Based Endocrine Disrupting Properties Assessment Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Endocrine Disrupting Properties Assessment Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Endocrine Disrupting Properties Assessment Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Endocrine Disrupting Properties Assessment Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 In Vitro (Cell-based) Testing
5.2.2 In Vivo (Animal) Testing
5.2.3 In Silico (Computational) Modeling
5.2.4 Others
5.3 Market Segment by Type
5.3.1 World Endocrine Disrupting Properties Assessment Market Size by Type (2021-2026)
5.3.2 World Endocrine Disrupting Properties Assessment Market Size by Type (2027-2032)
5.3.3 World Endocrine Disrupting Properties Assessment Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY ENDOCRINE PATHWAY
6.1 World Endocrine Disrupting Properties Assessment Market Size Overview by Endocrine Pathway: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Endocrine Pathway
6.2.1 Estrogen Pathway Assessment
6.2.2 Androgen Pathway Assessment
6.2.3 Thyroid Pathway Assessment
6.2.4 Steroid Synthesis Pathway Assessment
6.2.5 Others
6.3 Market Segment by Endocrine Pathway
6.3.1 World Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway (2021-2026)
6.3.2 World Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway (2027-2032)
6.3.3 World Endocrine Disrupting Properties Assessment Market Size Market Share by Endocrine Pathway (2027-2032)
7 MARKET ANALYSIS BY APPLICATION
7.1 World Endocrine Disrupting Properties Assessment Market Size Overview by Application: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Application
7.2.1 Environmental Monitoring
7.2.2 Food Safety
7.2.3 Cosmetics and Personal Care Products
7.2.4 Public Health and Disease Prevention
7.2.5 Others
7.3 Market Segment by Application
7.3.1 World Endocrine Disrupting Properties Assessment Market Size by Application (2021-2026)
7.3.2 World Endocrine Disrupting Properties Assessment Market Size by Application (2027-2032)
7.3.3 World Endocrine Disrupting Properties Assessment Market Size Market Share by Application (2021-2032)
8 COMPANY PROFILES
8.1 Labcorp
8.1.1 Labcorp Details
8.1.2 Labcorp Major Business
8.1.3 Labcorp Endocrine Disrupting Properties Assessment Product and Services
8.1.4 Labcorp Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.1.5 Labcorp Recent Developments/Updates
8.1.6 Labcorp Competitive Strengths & Weaknesses
8.2 Eurofins Scientific
8.2.1 Eurofins Scientific Details
8.2.2 Eurofins Scientific Major Business
8.2.3 Eurofins Scientific Endocrine Disrupting Properties Assessment Product and Services
8.2.4 Eurofins Scientific Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.2.5 Eurofins Scientific Recent Developments/Updates
8.2.6 Eurofins Scientific Competitive Strengths & Weaknesses
8.3 Intertek
8.3.1 Intertek Details
8.3.2 Intertek Major Business
8.3.3 Intertek Endocrine Disrupting Properties Assessment Product and Services
8.3.4 Intertek Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.3.5 Intertek Recent Developments/Updates
8.3.6 Intertek Competitive Strengths & Weaknesses
8.4 Charles River Laboratories
8.4.1 Charles River Laboratories Details
8.4.2 Charles River Laboratories Major Business
8.4.3 Charles River Laboratories Endocrine Disrupting Properties Assessment Product and Services
8.4.4 Charles River Laboratories Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.4.5 Charles River Laboratories Recent Developments/Updates
8.4.6 Charles River Laboratories Competitive Strengths & Weaknesses
8.5 PerkinElmer
8.5.1 PerkinElmer Details
8.5.2 PerkinElmer Major Business
8.5.3 PerkinElmer Endocrine Disrupting Properties Assessment Product and Services
8.5.4 PerkinElmer Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.5.5 PerkinElmer Recent Developments/Updates
8.5.6 PerkinElmer Competitive Strengths & Weaknesses
8.6 Smithers
8.6.1 Smithers Details
8.6.2 Smithers Major Business
8.6.3 Smithers Endocrine Disrupting Properties Assessment Product and Services
8.6.4 Smithers Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.6.5 Smithers Recent Developments/Updates
8.6.6 Smithers Competitive Strengths & Weaknesses
8.7 Fera Science
8.7.1 Fera Science Details
8.7.2 Fera Science Major Business
8.7.3 Fera Science Endocrine Disrupting Properties Assessment Product and Services
8.7.4 Fera Science Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.7.5 Fera Science Recent Developments/Updates
8.7.6 Fera Science Competitive Strengths & Weaknesses
8.8 Staphyt
8.8.1 Staphyt Details
8.8.2 Staphyt Major Business
8.8.3 Staphyt Endocrine Disrupting Properties Assessment Product and Services
8.8.4 Staphyt Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.8.5 Staphyt Recent Developments/Updates
8.8.6 Staphyt Competitive Strengths & Weaknesses
8.9 TransGenic
8.9.1 TransGenic Details
8.9.2 TransGenic Major Business
8.9.3 TransGenic Endocrine Disrupting Properties Assessment Product and Services
8.9.4 TransGenic Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.9.5 TransGenic Recent Developments/Updates
8.9.6 TransGenic Competitive Strengths & Weaknesses
8.10 ToxStrategies
8.10.1 ToxStrategies Details
8.10.2 ToxStrategies Major Business
8.10.3 ToxStrategies Endocrine Disrupting Properties Assessment Product and Services
8.10.4 ToxStrategies Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.10.5 ToxStrategies Recent Developments/Updates
8.10.6 ToxStrategies Competitive Strengths & Weaknesses
8.11 LAUS
8.11.1 LAUS Details
8.11.2 LAUS Major Business
8.11.3 LAUS Endocrine Disrupting Properties Assessment Product and Services
8.11.4 LAUS Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.11.5 LAUS Recent Developments/Updates
8.11.6 LAUS Competitive Strengths & Weaknesses
8.12 Creative Bioarray
8.12.1 Creative Bioarray Details
8.12.2 Creative Bioarray Major Business
8.12.3 Creative Bioarray Endocrine Disrupting Properties Assessment Product and Services
8.12.4 Creative Bioarray Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.12.5 Creative Bioarray Recent Developments/Updates
8.12.6 Creative Bioarray Competitive Strengths & Weaknesses
8.13 Creative Proteomics
8.13.1 Creative Proteomics Details
8.13.2 Creative Proteomics Major Business
8.13.3 Creative Proteomics Endocrine Disrupting Properties Assessment Product and Services
8.13.4 Creative Proteomics Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.13.5 Creative Proteomics Recent Developments/Updates
8.13.6 Creative Proteomics Competitive Strengths & Weaknesses
8.14 Compliance Services International
8.14.1 Compliance Services International Details
8.14.2 Compliance Services International Major Business
8.14.3 Compliance Services International Endocrine Disrupting Properties Assessment Product and Services
8.14.4 Compliance Services International Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.14.5 Compliance Services International Recent Developments/Updates
8.14.6 Compliance Services International Competitive Strengths & Weaknesses
8.15 Xenometrix
8.15.1 Xenometrix Details
8.15.2 Xenometrix Major Business
8.15.3 Xenometrix Endocrine Disrupting Properties Assessment Product and Services
8.15.4 Xenometrix Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.15.5 Xenometrix Recent Developments/Updates
8.15.6 Xenometrix Competitive Strengths & Weaknesses
8.16 Shenyang SYRICI Testing
8.16.1 Shenyang SYRICI Testing Details
8.16.2 Shenyang SYRICI Testing Major Business
8.16.3 Shenyang SYRICI Testing Endocrine Disrupting Properties Assessment Product and Services
8.16.4 Shenyang SYRICI Testing Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026)
8.16.5 Shenyang SYRICI Testing Recent Developments/Updates
8.16.6 Shenyang SYRICI Testing Competitive Strengths & Weaknesses
9 INDUSTRY CHAIN ANALYSIS
9.1 Endocrine Disrupting Properties Assessment Industry Chain
9.2 Endocrine Disrupting Properties Assessment Upstream Analysis
9.3 Endocrine Disrupting Properties Assessment Midstream Analysis
9.4 Endocrine Disrupting Properties Assessment Downstream Analysis
10 RESEARCH FINDINGS AND CONCLUSION
11 APPENDIX
11.1 Methodology
11.2 Research Process and Data Source
11.3 Disclaimer
LIST OF TABLES
Table 1. World Endocrine Disrupting Properties Assessment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Endocrine Disrupting Properties Assessment Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Endocrine Disrupting Properties Assessment Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Endocrine Disrupting Properties Assessment Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Endocrine Disrupting Properties Assessment Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Endocrine Disrupting Properties Assessment Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Endocrine Disrupting Properties Assessment Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Endocrine Disrupting Properties Assessment Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Endocrine Disrupting Properties Assessment Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Endocrine Disrupting Properties Assessment Players in 2025
Table 12. World Endocrine Disrupting Properties Assessment Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Endocrine Disrupting Properties Assessment Company Evaluation Quadrant
Table 14. Head Office of Key Endocrine Disrupting Properties Assessment Players
Table 15. Endocrine Disrupting Properties Assessment Market: Company Product Type Footprint
Table 16. Endocrine Disrupting Properties Assessment Market: Company Product Application Footprint
Table 17. Endocrine Disrupting Properties Assessment Mergers & Acquisitions Activity
Table 18. United States VS China Endocrine Disrupting Properties Assessment Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Endocrine Disrupting Properties Assessment Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Endocrine Disrupting Properties Assessment Companies, Headquarters (States, Country)
Table 21. United States Based Companies Endocrine Disrupting Properties Assessment Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Endocrine Disrupting Properties Assessment Revenue Market Share (2021-2026)
Table 23. China Based Endocrine Disrupting Properties Assessment Companies, Headquarters (Province, Country)
Table 24. China Based Companies Endocrine Disrupting Properties Assessment Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Endocrine Disrupting Properties Assessment Revenue Market Share (2021-2026)
Table 26. Rest of World Based Endocrine Disrupting Properties Assessment Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Endocrine Disrupting Properties Assessment Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Endocrine Disrupting Properties Assessment Revenue Market Share (2021-2026)
Table 29. World Endocrine Disrupting Properties Assessment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Endocrine Disrupting Properties Assessment Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Endocrine Disrupting Properties Assessment Market Size by Type (2027-2032) & (USD Million)
Table 32. World Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway, (USD Million), 2021 & 2025 & 2032
Table 33. World Endocrine Disrupting Properties Assessment Market Size Value by Endocrine Pathway (2021-2026) & (USD Million)
Table 34. World Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway (2027-2032) & (USD Million)
Table 35. World Endocrine Disrupting Properties Assessment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 36. World Endocrine Disrupting Properties Assessment Market Size by Application (2021-2026) & (USD Million)
Table 37. World Endocrine Disrupting Properties Assessment Market Size by Application (2027-2032) & (USD Million)
Table 38. Labcorp Basic Information, Manufacturing Base and Competitors
Table 39. Labcorp Major Business
Table 40. Labcorp Endocrine Disrupting Properties Assessment Product and Services
Table 41. Labcorp Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 42. Labcorp Recent Developments/Updates
Table 43. Labcorp Competitive Strengths & Weaknesses
Table 44. Eurofins Scientific Basic Information, Manufacturing Base and Competitors
Table 45. Eurofins Scientific Major Business
Table 46. Eurofins Scientific Endocrine Disrupting Properties Assessment Product and Services
Table 47. Eurofins Scientific Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Eurofins Scientific Recent Developments/Updates
Table 49. Eurofins Scientific Competitive Strengths & Weaknesses
Table 50. Intertek Basic Information, Manufacturing Base and Competitors
Table 51. Intertek Major Business
Table 52. Intertek Endocrine Disrupting Properties Assessment Product and Services
Table 53. Intertek Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. Intertek Recent Developments/Updates
Table 55. Intertek Competitive Strengths & Weaknesses
Table 56. Charles River Laboratories Basic Information, Manufacturing Base and Competitors
Table 57. Charles River Laboratories Major Business
Table 58. Charles River Laboratories Endocrine Disrupting Properties Assessment Product and Services
Table 59. Charles River Laboratories Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Charles River Laboratories Recent Developments/Updates
Table 61. Charles River Laboratories Competitive Strengths & Weaknesses
Table 62. PerkinElmer Basic Information, Manufacturing Base and Competitors
Table 63. PerkinElmer Major Business
Table 64. PerkinElmer Endocrine Disrupting Properties Assessment Product and Services
Table 65. PerkinElmer Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. PerkinElmer Recent Developments/Updates
Table 67. PerkinElmer Competitive Strengths & Weaknesses
Table 68. Smithers Basic Information, Manufacturing Base and Competitors
Table 69. Smithers Major Business
Table 70. Smithers Endocrine Disrupting Properties Assessment Product and Services
Table 71. Smithers Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Smithers Recent Developments/Updates
Table 73. Smithers Competitive Strengths & Weaknesses
Table 74. Fera Science Basic Information, Manufacturing Base and Competitors
Table 75. Fera Science Major Business
Table 76. Fera Science Endocrine Disrupting Properties Assessment Product and Services
Table 77. Fera Science Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Fera Science Recent Developments/Updates
Table 79. Fera Science Competitive Strengths & Weaknesses
Table 80. Staphyt Basic Information, Manufacturing Base and Competitors
Table 81. Staphyt Major Business
Table 82. Staphyt Endocrine Disrupting Properties Assessment Product and Services
Table 83. Staphyt Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. Staphyt Recent Developments/Updates
Table 85. Staphyt Competitive Strengths & Weaknesses
Table 86. TransGenic Basic Information, Manufacturing Base and Competitors
Table 87. TransGenic Major Business
Table 88. TransGenic Endocrine Disrupting Properties Assessment Product and Services
Table 89. TransGenic Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. TransGenic Recent Developments/Updates
Table 91. TransGenic Competitive Strengths & Weaknesses
Table 92. ToxStrategies Basic Information, Manufacturing Base and Competitors
Table 93. ToxStrategies Major Business
Table 94. ToxStrategies Endocrine Disrupting Properties Assessment Product and Services
Table 95. ToxStrategies Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 96. ToxStrategies Recent Developments/Updates
Table 97. ToxStrategies Competitive Strengths & Weaknesses
Table 98. LAUS Basic Information, Manufacturing Base and Competitors
Table 99. LAUS Major Business
Table 100. LAUS Endocrine Disrupting Properties Assessment Product and Services
Table 101. LAUS Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 102. LAUS Recent Developments/Updates
Table 103. LAUS Competitive Strengths & Weaknesses
Table 104. Creative Bioarray Basic Information, Manufacturing Base and Competitors
Table 105. Creative Bioarray Major Business
Table 106. Creative Bioarray Endocrine Disrupting Properties Assessment Product and Services
Table 107. Creative Bioarray Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 108. Creative Bioarray Recent Developments/Updates
Table 109. Creative Bioarray Competitive Strengths & Weaknesses
Table 110. Creative Proteomics Basic Information, Manufacturing Base and Competitors
Table 111. Creative Proteomics Major Business
Table 112. Creative Proteomics Endocrine Disrupting Properties Assessment Product and Services
Table 113. Creative Proteomics Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 114. Creative Proteomics Recent Developments/Updates
Table 115. Creative Proteomics Competitive Strengths & Weaknesses
Table 116. Compliance Services International Basic Information, Manufacturing Base and Competitors
Table 117. Compliance Services International Major Business
Table 118. Compliance Services International Endocrine Disrupting Properties Assessment Product and Services
Table 119. Compliance Services International Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 120. Compliance Services International Recent Developments/Updates
Table 121. Compliance Services International Competitive Strengths & Weaknesses
Table 122. Xenometrix Basic Information, Manufacturing Base and Competitors
Table 123. Xenometrix Major Business
Table 124. Xenometrix Endocrine Disrupting Properties Assessment Product and Services
Table 125. Xenometrix Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 126. Xenometrix Recent Developments/Updates
Table 127. Xenometrix Competitive Strengths & Weaknesses
Table 128. Shenyang SYRICI Testing Basic Information, Manufacturing Base and Competitors
Table 129. Shenyang SYRICI Testing Major Business
Table 130. Shenyang SYRICI Testing Endocrine Disrupting Properties Assessment Product and Services
Table 131. Shenyang SYRICI Testing Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 132. Shenyang SYRICI Testing Recent Developments/Updates
Table 133. Shenyang SYRICI Testing Competitive Strengths & Weaknesses
Table 134. Global Key Players of Endocrine Disrupting Properties Assessment Upstream (Raw Materials)
Table 135. Global Endocrine Disrupting Properties Assessment Typical Customers
Table 1. World Endocrine Disrupting Properties Assessment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Endocrine Disrupting Properties Assessment Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Endocrine Disrupting Properties Assessment Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Endocrine Disrupting Properties Assessment Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Endocrine Disrupting Properties Assessment Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Endocrine Disrupting Properties Assessment Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Endocrine Disrupting Properties Assessment Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Endocrine Disrupting Properties Assessment Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Endocrine Disrupting Properties Assessment Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Endocrine Disrupting Properties Assessment Players in 2025
Table 12. World Endocrine Disrupting Properties Assessment Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Endocrine Disrupting Properties Assessment Company Evaluation Quadrant
Table 14. Head Office of Key Endocrine Disrupting Properties Assessment Players
Table 15. Endocrine Disrupting Properties Assessment Market: Company Product Type Footprint
Table 16. Endocrine Disrupting Properties Assessment Market: Company Product Application Footprint
Table 17. Endocrine Disrupting Properties Assessment Mergers & Acquisitions Activity
Table 18. United States VS China Endocrine Disrupting Properties Assessment Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Endocrine Disrupting Properties Assessment Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Endocrine Disrupting Properties Assessment Companies, Headquarters (States, Country)
Table 21. United States Based Companies Endocrine Disrupting Properties Assessment Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Endocrine Disrupting Properties Assessment Revenue Market Share (2021-2026)
Table 23. China Based Endocrine Disrupting Properties Assessment Companies, Headquarters (Province, Country)
Table 24. China Based Companies Endocrine Disrupting Properties Assessment Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Endocrine Disrupting Properties Assessment Revenue Market Share (2021-2026)
Table 26. Rest of World Based Endocrine Disrupting Properties Assessment Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Endocrine Disrupting Properties Assessment Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Endocrine Disrupting Properties Assessment Revenue Market Share (2021-2026)
Table 29. World Endocrine Disrupting Properties Assessment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Endocrine Disrupting Properties Assessment Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Endocrine Disrupting Properties Assessment Market Size by Type (2027-2032) & (USD Million)
Table 32. World Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway, (USD Million), 2021 & 2025 & 2032
Table 33. World Endocrine Disrupting Properties Assessment Market Size Value by Endocrine Pathway (2021-2026) & (USD Million)
Table 34. World Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway (2027-2032) & (USD Million)
Table 35. World Endocrine Disrupting Properties Assessment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 36. World Endocrine Disrupting Properties Assessment Market Size by Application (2021-2026) & (USD Million)
Table 37. World Endocrine Disrupting Properties Assessment Market Size by Application (2027-2032) & (USD Million)
Table 38. Labcorp Basic Information, Manufacturing Base and Competitors
Table 39. Labcorp Major Business
Table 40. Labcorp Endocrine Disrupting Properties Assessment Product and Services
Table 41. Labcorp Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 42. Labcorp Recent Developments/Updates
Table 43. Labcorp Competitive Strengths & Weaknesses
Table 44. Eurofins Scientific Basic Information, Manufacturing Base and Competitors
Table 45. Eurofins Scientific Major Business
Table 46. Eurofins Scientific Endocrine Disrupting Properties Assessment Product and Services
Table 47. Eurofins Scientific Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Eurofins Scientific Recent Developments/Updates
Table 49. Eurofins Scientific Competitive Strengths & Weaknesses
Table 50. Intertek Basic Information, Manufacturing Base and Competitors
Table 51. Intertek Major Business
Table 52. Intertek Endocrine Disrupting Properties Assessment Product and Services
Table 53. Intertek Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. Intertek Recent Developments/Updates
Table 55. Intertek Competitive Strengths & Weaknesses
Table 56. Charles River Laboratories Basic Information, Manufacturing Base and Competitors
Table 57. Charles River Laboratories Major Business
Table 58. Charles River Laboratories Endocrine Disrupting Properties Assessment Product and Services
Table 59. Charles River Laboratories Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Charles River Laboratories Recent Developments/Updates
Table 61. Charles River Laboratories Competitive Strengths & Weaknesses
Table 62. PerkinElmer Basic Information, Manufacturing Base and Competitors
Table 63. PerkinElmer Major Business
Table 64. PerkinElmer Endocrine Disrupting Properties Assessment Product and Services
Table 65. PerkinElmer Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. PerkinElmer Recent Developments/Updates
Table 67. PerkinElmer Competitive Strengths & Weaknesses
Table 68. Smithers Basic Information, Manufacturing Base and Competitors
Table 69. Smithers Major Business
Table 70. Smithers Endocrine Disrupting Properties Assessment Product and Services
Table 71. Smithers Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Smithers Recent Developments/Updates
Table 73. Smithers Competitive Strengths & Weaknesses
Table 74. Fera Science Basic Information, Manufacturing Base and Competitors
Table 75. Fera Science Major Business
Table 76. Fera Science Endocrine Disrupting Properties Assessment Product and Services
Table 77. Fera Science Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Fera Science Recent Developments/Updates
Table 79. Fera Science Competitive Strengths & Weaknesses
Table 80. Staphyt Basic Information, Manufacturing Base and Competitors
Table 81. Staphyt Major Business
Table 82. Staphyt Endocrine Disrupting Properties Assessment Product and Services
Table 83. Staphyt Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. Staphyt Recent Developments/Updates
Table 85. Staphyt Competitive Strengths & Weaknesses
Table 86. TransGenic Basic Information, Manufacturing Base and Competitors
Table 87. TransGenic Major Business
Table 88. TransGenic Endocrine Disrupting Properties Assessment Product and Services
Table 89. TransGenic Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. TransGenic Recent Developments/Updates
Table 91. TransGenic Competitive Strengths & Weaknesses
Table 92. ToxStrategies Basic Information, Manufacturing Base and Competitors
Table 93. ToxStrategies Major Business
Table 94. ToxStrategies Endocrine Disrupting Properties Assessment Product and Services
Table 95. ToxStrategies Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 96. ToxStrategies Recent Developments/Updates
Table 97. ToxStrategies Competitive Strengths & Weaknesses
Table 98. LAUS Basic Information, Manufacturing Base and Competitors
Table 99. LAUS Major Business
Table 100. LAUS Endocrine Disrupting Properties Assessment Product and Services
Table 101. LAUS Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 102. LAUS Recent Developments/Updates
Table 103. LAUS Competitive Strengths & Weaknesses
Table 104. Creative Bioarray Basic Information, Manufacturing Base and Competitors
Table 105. Creative Bioarray Major Business
Table 106. Creative Bioarray Endocrine Disrupting Properties Assessment Product and Services
Table 107. Creative Bioarray Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 108. Creative Bioarray Recent Developments/Updates
Table 109. Creative Bioarray Competitive Strengths & Weaknesses
Table 110. Creative Proteomics Basic Information, Manufacturing Base and Competitors
Table 111. Creative Proteomics Major Business
Table 112. Creative Proteomics Endocrine Disrupting Properties Assessment Product and Services
Table 113. Creative Proteomics Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 114. Creative Proteomics Recent Developments/Updates
Table 115. Creative Proteomics Competitive Strengths & Weaknesses
Table 116. Compliance Services International Basic Information, Manufacturing Base and Competitors
Table 117. Compliance Services International Major Business
Table 118. Compliance Services International Endocrine Disrupting Properties Assessment Product and Services
Table 119. Compliance Services International Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 120. Compliance Services International Recent Developments/Updates
Table 121. Compliance Services International Competitive Strengths & Weaknesses
Table 122. Xenometrix Basic Information, Manufacturing Base and Competitors
Table 123. Xenometrix Major Business
Table 124. Xenometrix Endocrine Disrupting Properties Assessment Product and Services
Table 125. Xenometrix Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 126. Xenometrix Recent Developments/Updates
Table 127. Xenometrix Competitive Strengths & Weaknesses
Table 128. Shenyang SYRICI Testing Basic Information, Manufacturing Base and Competitors
Table 129. Shenyang SYRICI Testing Major Business
Table 130. Shenyang SYRICI Testing Endocrine Disrupting Properties Assessment Product and Services
Table 131. Shenyang SYRICI Testing Endocrine Disrupting Properties Assessment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 132. Shenyang SYRICI Testing Recent Developments/Updates
Table 133. Shenyang SYRICI Testing Competitive Strengths & Weaknesses
Table 134. Global Key Players of Endocrine Disrupting Properties Assessment Upstream (Raw Materials)
Table 135. Global Endocrine Disrupting Properties Assessment Typical Customers
LIST OF FIGURES
Figure 1. Endocrine Disrupting Properties Assessment Picture
Figure 2. World Endocrine Disrupting Properties Assessment Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Endocrine Disrupting Properties Assessment Total Revenue (2021-2032) & (USD Million)
Figure 4. World Endocrine Disrupting Properties Assessment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Endocrine Disrupting Properties Assessment Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 13. Endocrine Disrupting Properties Assessment Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 16. World Endocrine Disrupting Properties Assessment Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 18. China Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 23. India Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Endocrine Disrupting Properties Assessment by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Endocrine Disrupting Properties Assessment Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Endocrine Disrupting Properties Assessment Markets in 2025
Figure 27. United States VS China: Endocrine Disrupting Properties Assessment Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Endocrine Disrupting Properties Assessment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Endocrine Disrupting Properties Assessment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Endocrine Disrupting Properties Assessment Market Size Market Share by Type in 2025
Figure 31. In Vitro (Cell-based) Testing
Figure 32. In Vivo (Animal) Testing
Figure 33. In Silico (Computational) Modeling
Figure 34. Others
Figure 35. World Endocrine Disrupting Properties Assessment Market Size Market Share by Type (2021-2032)
Figure 36. World Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway, (USD Million), 2021 & 2025 & 2032
Figure 37. World Endocrine Disrupting Properties Assessment Market Size Market Share by Endocrine Pathway in 2025
Figure 38. Estrogen Pathway Assessment
Figure 39. Androgen Pathway Assessment
Figure 40. Thyroid Pathway Assessment
Figure 41. Steroid Synthesis Pathway Assessment
Figure 42. Others
Figure 43. World Endocrine Disrupting Properties Assessment Market Size Market Share by Endocrine Pathway (2021-2032)
Figure 44. World Endocrine Disrupting Properties Assessment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 45. World Endocrine Disrupting Properties Assessment Market Size Market Share by Application in 2025
Figure 46. Environmental Monitoring
Figure 47. Food Safety
Figure 48. Cosmetics and Personal Care Products
Figure 49. Public Health and Disease Prevention
Figure 50. Others
Figure 51. World Endocrine Disrupting Properties Assessment Market Size Market Share by Application (2021-2032)
Figure 52. Endocrine Disrupting Properties Assessment Industrial Chain
Figure 53. Methodology
Figure 54. Research Process and Data Source
Figure 1. Endocrine Disrupting Properties Assessment Picture
Figure 2. World Endocrine Disrupting Properties Assessment Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Endocrine Disrupting Properties Assessment Total Revenue (2021-2032) & (USD Million)
Figure 4. World Endocrine Disrupting Properties Assessment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Endocrine Disrupting Properties Assessment Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Endocrine Disrupting Properties Assessment Revenue (2021-2032) & (USD Million)
Figure 13. Endocrine Disrupting Properties Assessment Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 16. World Endocrine Disrupting Properties Assessment Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 18. China Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 23. India Endocrine Disrupting Properties Assessment Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Endocrine Disrupting Properties Assessment by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Endocrine Disrupting Properties Assessment Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Endocrine Disrupting Properties Assessment Markets in 2025
Figure 27. United States VS China: Endocrine Disrupting Properties Assessment Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Endocrine Disrupting Properties Assessment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Endocrine Disrupting Properties Assessment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Endocrine Disrupting Properties Assessment Market Size Market Share by Type in 2025
Figure 31. In Vitro (Cell-based) Testing
Figure 32. In Vivo (Animal) Testing
Figure 33. In Silico (Computational) Modeling
Figure 34. Others
Figure 35. World Endocrine Disrupting Properties Assessment Market Size Market Share by Type (2021-2032)
Figure 36. World Endocrine Disrupting Properties Assessment Market Size by Endocrine Pathway, (USD Million), 2021 & 2025 & 2032
Figure 37. World Endocrine Disrupting Properties Assessment Market Size Market Share by Endocrine Pathway in 2025
Figure 38. Estrogen Pathway Assessment
Figure 39. Androgen Pathway Assessment
Figure 40. Thyroid Pathway Assessment
Figure 41. Steroid Synthesis Pathway Assessment
Figure 42. Others
Figure 43. World Endocrine Disrupting Properties Assessment Market Size Market Share by Endocrine Pathway (2021-2032)
Figure 44. World Endocrine Disrupting Properties Assessment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 45. World Endocrine Disrupting Properties Assessment Market Size Market Share by Application in 2025
Figure 46. Environmental Monitoring
Figure 47. Food Safety
Figure 48. Cosmetics and Personal Care Products
Figure 49. Public Health and Disease Prevention
Figure 50. Others
Figure 51. World Endocrine Disrupting Properties Assessment Market Size Market Share by Application (2021-2032)
Figure 52. Endocrine Disrupting Properties Assessment Industrial Chain
Figure 53. Methodology
Figure 54. Research Process and Data Source
